<?xml version="1.0" encoding="UTF-8"?>
<mods xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
      version="3.7"
      xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-7.xsd">
   <titleInfo>
      <title>Anti-oxidant profile of Divya-Peedantak-Vati abates paclitaxel-induced hyperalgesia and allodynia in CD-1 mice model of neuropathic pain</title>
   </titleInfo>
   <name type="personal" usage="primary">
      <namePart type="given">Acharya</namePart>
      <namePart type="family">Balkrishna</namePart>
      <displayForm>Balkrishna, Acharya</displayForm>
      <affiliation>Drug Discovery and Development Division, Patanjali Research Institute, Haridwar, Uttarakhand 249405, India</affiliation>
      <affiliation>Department of Allied and Applied Sciences, University of Patanjali, Haridwar, Uttarakhand, India</affiliation>
      <role>
         <roleTerm type="text">author</roleTerm>
      </role>
   </name>
   <name type="personal">
      <namePart type="given">Shadrak</namePart>
      <namePart type="family">Karumuri</namePart>
      <displayForm>Karumuri, Shadrak</displayForm>
      <affiliation>Drug Discovery and Development Division, Patanjali Research Institute, Haridwar, Uttarakhand 249405, India</affiliation>
      <role>
         <roleTerm type="text">author</roleTerm>
      </role>
   </name>
   <name type="personal">
      <namePart type="given">Sachin S</namePart>
      <namePart type="family">Sakat</namePart>
      <displayForm>Sakat, Sachin S</displayForm>
      <affiliation>Drug Discovery and Development Division, Patanjali Research Institute, Haridwar, Uttarakhand 249405, India</affiliation>
      <role>
         <roleTerm type="text">author</roleTerm>
      </role>
   </name>
   <name type="personal">
      <namePart type="given">Swati</namePart>
      <namePart type="family">Haldar</namePart>
      <displayForm>Haldar, Swati</displayForm>
      <affiliation>Drug Discovery and Development Division, Patanjali Research Institute, Haridwar, Uttarakhand 249405, India</affiliation>
      <role>
         <roleTerm type="text">author</roleTerm>
      </role>
   </name>
   <name type="personal">
      <namePart type="given">Anurag</namePart>
      <namePart type="family">Varshney</namePart>
      <displayForm>Varshney, Anurag</displayForm>
      <affiliation>Drug Discovery and Development Division, Patanjali Research Institute, Haridwar, Uttarakhand 249405, India</affiliation>
      <affiliation>Department of Allied and Applied Sciences, University of Patanjali, Haridwar, Uttarakhand, India</affiliation>
      <affiliation>Special Centre for Systems Medicine, Jawaharlal Nehru University, New Delhi, India</affiliation>
      <role>
         <roleTerm type="text">author</roleTerm>
      </role>
   </name>
   <typeOfResource>text</typeOfResource>
   <genre>article</genre>
   <originInfo>
      <dateIssued encoding="w3cdtf" keyDate="yes">2022-05</dateIssued>
   </originInfo>
   <language>
      <languageTerm type="code" authority="iso639-2b">eng</languageTerm>
      <languageTerm type="text">English</languageTerm>
   </language>
   <abstract>Paclitaxel (PTX) is a known chemotherapeutic agent, used to treat different types of cancers. However, it leads to neuropathic pain in a sizeable proportion of the patients. Currently, analgesics, opioids, tricyclic antidepressants and anticonvulsants are prescribed for PTX-mediated chemotherapy-induced peripheral neuropathy (CIPN). However, these treatments have acute side-effects, creating a need for safer alternative treatment option. PTX-mediated CIPN has nociceptive outcomes, like, allodynia and hyperalgesia with an underlying inflammatory and oxidative causes. The herbo-mineral medicine, Divya-Peedantak-Vati (DPV) is known for its effectivity against joint pain and inflammatory disorders in Ayurveda, a traditional Indian system of medicine. Therefore, anti-neuropathic potential of DPV was assessed in PTX-induced neuropathic CD-1 mice, with allodynia and hyperalgesia, as the clinically relevant endpoints. DPV was investigated for its nociception-modulatory and anti-inflammatory effects under in vivo and in vitro conditions. DPV treatment exhibited notable anti-allodynic and anti-hyperalgesic effects in a dose dependent manner, and displayed prominent anti-oxidant effects in the sciatic nerve of the study animals. It also moderated, in a dose dependent manner, the levels of cytokine, interleukin-1beta (IL-1β) and tumor necrosis factor alpha (TNF-α) induced nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling. The novelty of this study lies in the demonstration of the anti-neuropathic potential and elucidation of anti-neuropathic mode-of-action of an herbal medicine. Taken together, this study showed that DPV could well be an effective alternative healing option for PTX-mediated CIPN. </abstract>
   <subject>
      <topic>Paclitaxel</topic>
   </subject>
   <subject>
      <topic>Divya-Peedantak-Vati</topic>
   </subject>
   <subject>
      <topic>Ayurvedic medicine</topic>
   </subject>
   <subject>
      <topic>CIPN model</topic>
   </subject>
   <subject>
      <topic>Anti-oxidant</topic>
   </subject>
   <subject>
      <topic>Anti-inflammatory</topic>
   </subject>
   <relatedItem type="host">
      <titleInfo>
         <title>Phytomedicine Plus</title>
      </titleInfo>
      <originInfo>
         <publisher>Elsevier B.V.</publisher>
      </originInfo>
      <identifier type="issn">2667-0313</identifier>
      <part>
         <detail type="volume">
            <number>2</number>
            <caption>v.</caption>
         </detail>
         <detail type="issue">
            <number>2</number>
            <caption>no.</caption>
         </detail>
         <text type="display-date">May 2022</text>
         <text type="year">2022</text>
         <text type="month">May</text>
         <extent unit="pages">
            <start>100229</start>
         </extent>
      </part>
   </relatedItem>
   <identifier type="doi">10.1016/j.phyplu.2022.100229</identifier>
   <location>
      <url>http://dx.doi.org/10.1016/j.phyplu.2022.100229</url>
   </location>
   <identifier type="pii">S2667-0313(22)00015-X</identifier>
   <accessCondition type="use and reproduction"
                    displayLabel="Creative Commons Attribution 4.0 Generic (CC BY-NC-ND 4.0)">
      <program xmlns="https://data.crossref.org/schemas/AccessIndicators.xsd">
         <licence_ref applies_to="reuse" start_date="2022-01-26"/>
         <licence_ref>http://creativecommons.org/licenses/by-nc-nd/4.0/</licence_ref>
      </program>
   </accessCondition>
   <extension>
      <vendorName/>
      <archiveFile/>
      <originalFile>file:/C:/Users/Carlos.Martinez/OneDrive%20-%20USDA/XML_projects/OpenAccess/OpenAccess/transform/source/sourcefiles/576450669703096969-00001/2667-0313/S2667031322X0002X/S266703132200015X/S266703132200015X.xml</originalFile>
      <workingDirectory>C:\Users\Carlos.Martinez\OneDrive - USDA\XML_projects\OpenAccess\OpenAccess\transform\result\</workingDirectory>
   </extension>
</mods>
